DOP2016000096A - Nuevo compuesto para el tratamiento de hipoglicemia severa - Google Patents
Nuevo compuesto para el tratamiento de hipoglicemia severaInfo
- Publication number
- DOP2016000096A DOP2016000096A DO2016000096A DO2016000096A DOP2016000096A DO P2016000096 A DOP2016000096 A DO P2016000096A DO 2016000096 A DO2016000096 A DO 2016000096A DO 2016000096 A DO2016000096 A DO 2016000096A DO P2016000096 A DOP2016000096 A DO P2016000096A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- lys
- ser
- leu
- treatment
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Removal Of Specific Substances (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un compuesto que comprende la secuencia de aminoácido de His-Ala-Gln-Gly-Thr-Phe-Leu-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-(Aib)-Lys-Lys-Ala-Gln-Glu-Phe-Val-Glu-Trp-Leu-Leu-Lys-Thr-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Lys-Ser-Lys-NH2 (SEC ID NO: 2) con solubilidad y estabilidades físicas y químicas mejoradas sobre el glucagón humano útil en el tratamiento de la diabetes y/o obesidad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361917597P | 2013-12-18 | 2013-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2016000096A true DOP2016000096A (es) | 2016-08-15 |
Family
ID=52278802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2016000096A DOP2016000096A (es) | 2013-12-18 | 2016-04-27 | Nuevo compuesto para el tratamiento de hipoglicemia severa |
Country Status (27)
Country | Link |
---|---|
US (1) | US9695225B2 (es) |
EP (1) | EP3083668A1 (es) |
JP (1) | JP2017509584A (es) |
KR (1) | KR20160075825A (es) |
CN (1) | CN105814076A (es) |
AP (1) | AP2016009242A0 (es) |
AR (1) | AR098614A1 (es) |
AU (1) | AU2014366424B2 (es) |
BR (1) | BR112016012067A2 (es) |
CA (1) | CA2928985A1 (es) |
CL (1) | CL2016001472A1 (es) |
CR (1) | CR20160226A (es) |
DO (1) | DOP2016000096A (es) |
EA (1) | EA201690914A1 (es) |
EC (1) | ECSP16024798A (es) |
GT (1) | GT201600117A (es) |
HK (1) | HK1224304A1 (es) |
IL (1) | IL245400A0 (es) |
MA (1) | MA39109B1 (es) |
MX (1) | MX2016007982A (es) |
NZ (1) | NZ719463A (es) |
PE (1) | PE20160848A1 (es) |
PH (1) | PH12016501182A1 (es) |
SG (1) | SG11201604154SA (es) |
TN (1) | TN2016000181A1 (es) |
TW (1) | TW201609127A (es) |
WO (1) | WO2015094875A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
WO2019140024A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
JP7212171B2 (ja) | 2019-02-05 | 2023-01-24 | イーライ リリー アンド カンパニー | グルカゴン類似体アゴニストおよびその使用方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1891105E (pt) | 2005-06-13 | 2012-06-27 | Imp Innovations Ltd | Análogos de oxintomodulina e seus efeitos sobre o comportamento da alimentação |
ES2628063T3 (es) | 2007-01-05 | 2017-08-01 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos |
US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
ES2558842T3 (es) | 2008-06-17 | 2016-02-09 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
CN102088989B (zh) * | 2008-06-17 | 2014-11-26 | 印第安纳大学研究及科技有限公司 | 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物 |
KR20120087875A (ko) | 2009-06-16 | 2012-08-07 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Gip 수용체-활성 글루카곤 화합물 |
US20120148586A1 (en) * | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
JP6050746B2 (ja) * | 2010-05-13 | 2016-12-21 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Gタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド |
NZ612297A (en) | 2010-12-22 | 2015-10-30 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
DK2718318T3 (en) * | 2011-06-10 | 2018-11-05 | Hanmi Science Co Ltd | New oxyntomodulin derivatives and pharmaceutical compositions for the treatment of obesity comprising these |
US9309301B2 (en) | 2011-06-22 | 2016-04-12 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
EP2729493B1 (en) * | 2011-07-04 | 2020-06-10 | IP2IPO Innovations Limited | Novel compounds and their effects on feeding behaviour |
JP6311708B2 (ja) * | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Gip受容体活性を示すグルカゴンアナローグ |
-
2014
- 2014-12-04 AR ARP140104512A patent/AR098614A1/es unknown
- 2014-12-05 TW TW103142472A patent/TW201609127A/zh unknown
- 2014-12-11 TN TN2016000181A patent/TN2016000181A1/en unknown
- 2014-12-11 PE PE2016000762A patent/PE20160848A1/es not_active Application Discontinuation
- 2014-12-11 AU AU2014366424A patent/AU2014366424B2/en not_active Ceased
- 2014-12-11 EA EA201690914A patent/EA201690914A1/ru unknown
- 2014-12-11 WO PCT/US2014/069643 patent/WO2015094875A1/en active Application Filing
- 2014-12-11 JP JP2016540547A patent/JP2017509584A/ja active Pending
- 2014-12-11 NZ NZ719463A patent/NZ719463A/en not_active IP Right Cessation
- 2014-12-11 BR BR112016012067A patent/BR112016012067A2/pt active Search and Examination
- 2014-12-11 CA CA2928985A patent/CA2928985A1/en not_active Abandoned
- 2014-12-11 CN CN201480067303.3A patent/CN105814076A/zh active Pending
- 2014-12-11 SG SG11201604154SA patent/SG11201604154SA/en unknown
- 2014-12-11 MX MX2016007982A patent/MX2016007982A/es unknown
- 2014-12-11 MA MA39109A patent/MA39109B1/fr unknown
- 2014-12-11 US US15/103,092 patent/US9695225B2/en not_active Expired - Fee Related
- 2014-12-11 KR KR1020167015879A patent/KR20160075825A/ko not_active Application Discontinuation
- 2014-12-11 EP EP14821985.0A patent/EP3083668A1/en not_active Withdrawn
-
2016
- 2016-04-27 DO DO2016000096A patent/DOP2016000096A/es unknown
- 2016-05-02 IL IL245400A patent/IL245400A0/en unknown
- 2016-05-18 CR CR20160226A patent/CR20160226A/es unknown
- 2016-06-13 CL CL2016001472A patent/CL2016001472A1/es unknown
- 2016-06-15 GT GT201600117A patent/GT201600117A/es unknown
- 2016-06-16 EC ECIEPI201624798A patent/ECSP16024798A/es unknown
- 2016-06-17 PH PH12016501182A patent/PH12016501182A1/en unknown
- 2016-06-30 AP AP2016009242A patent/AP2016009242A0/en unknown
- 2016-10-27 HK HK16112377.0A patent/HK1224304A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20160075825A (ko) | 2016-06-29 |
CR20160226A (es) | 2016-07-12 |
US20160311881A1 (en) | 2016-10-27 |
AP2016009242A0 (en) | 2016-06-30 |
MA39109A1 (fr) | 2017-09-29 |
JP2017509584A (ja) | 2017-04-06 |
BR112016012067A2 (pt) | 2017-09-26 |
HK1224304A1 (zh) | 2017-08-18 |
WO2015094875A1 (en) | 2015-06-25 |
NZ719463A (en) | 2017-09-29 |
CL2016001472A1 (es) | 2017-03-10 |
IL245400A0 (en) | 2016-06-30 |
TN2016000181A1 (en) | 2017-10-06 |
ECSP16024798A (es) | 2017-05-31 |
AU2014366424B2 (en) | 2017-02-16 |
EA201690914A1 (ru) | 2016-09-30 |
US9695225B2 (en) | 2017-07-04 |
EP3083668A1 (en) | 2016-10-26 |
TW201609127A (zh) | 2016-03-16 |
MX2016007982A (es) | 2016-09-09 |
CN105814076A (zh) | 2016-07-27 |
PH12016501182A1 (en) | 2016-07-25 |
SG11201604154SA (en) | 2016-07-28 |
CA2928985A1 (en) | 2015-06-25 |
AU2014366424A1 (en) | 2016-05-19 |
PE20160848A1 (es) | 2016-09-10 |
AR098614A1 (es) | 2016-06-01 |
MA39109B1 (fr) | 2018-04-30 |
GT201600117A (es) | 2017-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017003185A1 (es) | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) | |
CY1121114T1 (el) | Αγωνιστες γλυκαγονης/glp-1 για τη θεραπεια της παχυσαρκιας | |
AR098741A1 (es) | Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón | |
AR098738A1 (es) | Análogos del péptido exendina-4 no acilados | |
AR102869A1 (es) | Composiciones de insulina de rápida acción | |
EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
UY35072A (es) | Derivados de exendina-4 como agonistas duales de GLP1/glucagón | |
UY35231A (es) | Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/Glucagón | |
UA118558C2 (uk) | Пептидна сполука | |
CR20120457A (es) | Peptidos novedosos y métodos para su preparación y uso | |
CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
BR112014013780A8 (pt) | transportador de seringa | |
UY35548A (es) | Péptidos terapéuticos para el tratamiento de trastornos metabólicos. | |
CY1117603T1 (el) | Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2 | |
CL2017002031A1 (es) | Formulación en polvo nasal para el tratamiento de hipoglicemia | |
CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
CR20170376A (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida | |
UY34575A (es) | Composiciones y métodos para el tratamiento de diabetes y/u obesidad | |
DOP2016000096A (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa | |
ECSP13012603A (es) | Nueva formulacion del cetp(1) | |
CL2016001473A1 (es) | Compuesto analogo del glucogeno (glp-1) que comprende acido alfa aminobutirico para el tratamiento de hipoglicemia. | |
AR098615A1 (es) | Péptido para el tratamiento de hipoglicemia severa | |
IN2013MU02576A (es) |